FDA Determines Regulatory Review Period for REXULTI Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for REXULTI, a human drug product, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.